The interaction of three potential anti-diabetic (VO)-O-IV compounds formed by picolinate (pic), 3-methylpicolinate (3-mepic) and 6-methylpicolinate (6-mepic) with hemoglobin (Hb) and red blood cells was studied with the combined application of spectroscopic (EPR), spectrophotometric (UV-Vis) and computational (DFT methods) techniques. In the ternary systems with hemoglobin, pic and 3-mepic (L) form mixed species cis-VOL2(Hb), with the equatorial binding of an accessible His residue, whereas 6-mepic forms VO(6-mepic)(OH)(Hb). The experiments about the uptake of (VO)-O-IV complexes by red blood cells indicate that only [VO(pic)(2)(H2O)] penetrates the erythrocyte membrane in a significant amount, whereas for [VO(3-mepic)(2)] and [VO(6-mepic)(2)] the hydrolytic reactions at physiological pH hinder the diffusion in the intracellular medium. Inside the red blood cells, the biotransformations depend mainly on the strength of the ligand. Pic and 3-mepic form cis-VOL2(Hb) and cis-VOL2(Cys-S ) with the equatorial coordination of a thiolate-S stemming from GSH or a membrane protein. Instead, the less thermodynamically stable compound, [VO(6-mepic)(2)], loses the two ligands after the interaction with the membrane or inside the erythrocytes to give the same species formed by free (VO2+)-O-IV ion: (VO) Hb(beta) and (VO)Hbc gamma, with (VO2+)-O-IV coordinated to the sites beta and gamma of hemoglobin, and VO(L-1, L-2) and VO(L-3, L-4), where L-1, L-2, L-3 and L-4 are generic red blood cell bioligands, such as proteins (for example, Hb) or low molecular mass (l.m.m.) components. The distribution of an insulin-enhancing V compound between the serum and the red blood cells may influence the mechanism of action and the activity of a V drug and explain the different effectiveness observed in the literature.

Uptake of potential anti-diabetic VIVO compounds of picolinate ligands by red blood cells / D., Sanna; M., Serra; G., Micera; Garribba, Eugenio. - In: INORGANICA CHIMICA ACTA. - ISSN 0020-1693. - 420:(2014), pp. 75-84. [10.1016/j.ica.2013.12.038]

Uptake of potential anti-diabetic VIVO compounds of picolinate ligands by red blood cells

GARRIBBA, Eugenio
2014

Abstract

The interaction of three potential anti-diabetic (VO)-O-IV compounds formed by picolinate (pic), 3-methylpicolinate (3-mepic) and 6-methylpicolinate (6-mepic) with hemoglobin (Hb) and red blood cells was studied with the combined application of spectroscopic (EPR), spectrophotometric (UV-Vis) and computational (DFT methods) techniques. In the ternary systems with hemoglobin, pic and 3-mepic (L) form mixed species cis-VOL2(Hb), with the equatorial binding of an accessible His residue, whereas 6-mepic forms VO(6-mepic)(OH)(Hb). The experiments about the uptake of (VO)-O-IV complexes by red blood cells indicate that only [VO(pic)(2)(H2O)] penetrates the erythrocyte membrane in a significant amount, whereas for [VO(3-mepic)(2)] and [VO(6-mepic)(2)] the hydrolytic reactions at physiological pH hinder the diffusion in the intracellular medium. Inside the red blood cells, the biotransformations depend mainly on the strength of the ligand. Pic and 3-mepic form cis-VOL2(Hb) and cis-VOL2(Cys-S ) with the equatorial coordination of a thiolate-S stemming from GSH or a membrane protein. Instead, the less thermodynamically stable compound, [VO(6-mepic)(2)], loses the two ligands after the interaction with the membrane or inside the erythrocytes to give the same species formed by free (VO2+)-O-IV ion: (VO) Hb(beta) and (VO)Hbc gamma, with (VO2+)-O-IV coordinated to the sites beta and gamma of hemoglobin, and VO(L-1, L-2) and VO(L-3, L-4), where L-1, L-2, L-3 and L-4 are generic red blood cell bioligands, such as proteins (for example, Hb) or low molecular mass (l.m.m.) components. The distribution of an insulin-enhancing V compound between the serum and the red blood cells may influence the mechanism of action and the activity of a V drug and explain the different effectiveness observed in the literature.
Uptake of potential anti-diabetic VIVO compounds of picolinate ligands by red blood cells / D., Sanna; M., Serra; G., Micera; Garribba, Eugenio. - In: INORGANICA CHIMICA ACTA. - ISSN 0020-1693. - 420:(2014), pp. 75-84. [10.1016/j.ica.2013.12.038]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/81933
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 37
social impact